Latest Content

Rediscovering My Sense of Faith Following a Colon Cancer Diagnosis

February 17th 2025, 6:00pm

By Carla Deschamps

Article

Faith, from my perspective, is believing in the unseen, and was something I rediscovered following my colon cancer diagnosis.

An Expert Explains The Risk and Outcomes of Primary Urothelial Cancer Treatment

February 17th 2025, 5:00pm

By Dr. Rohan Garje

Video

Primary urothelial cancer has variable histologies, making its treatment complex, leading to varied outcomes with high rates of recurrence in patients.

mpMRI Improves Initial Staging in Suspected Muscle-Invasive Bladder Cancer

February 17th 2025, 4:01pm

By Ryan Scott

Article

Among patients with suspected MIBC, the incorporation of mpMRI for initial staging prior to transurethral resection of bladder tumor was beneficial.

GAP Regimen May Not Improve Survival in Biliary Tract Cancer Subset

February 17th 2025, 2:00pm

By Spencer Feldman

Article

The addition of nab-paclitaxel to gemcitabine and cisplatin did not improve survival in advanced biliary tract cancer.

Treatment Intensification Adoption Differences Across Prostate Cancer

February 16th 2025, 7:00pm

By Dr. Neeraj Agarwal

Video

There are differences in prostate cancer treatment intensification adoption between academic and nonacademic physicians.

EBRT Regimens Show Long-Term Survival Outcomes in Prostate Cancer

February 16th 2025, 3:00pm

By Roman Fabbricatore

Article

Patients with intermediate-risk prostate cancer had a 15-year prostate cancer–specific survival rate of 91% with EBRT, with or without short-term ADT.

Outcomes May Be Consistent With Fotivda Alone or With Opdivo in Kidney Cancer Subset

February 15th 2025, 10:52pm

By Ashley Chan

Article

Patient-reported outcomes were similar for Fotivda with or without Opdivo in advanced clear cell RCC.

Opdivo Plus Cabometyx Safe, Effective in Advanced Renal Cell Carcinoma

February 15th 2025, 10:36pm

By Tim Cortese

Article

Opdivo plus Cabometyx resulted in a significant progression and survival benefits compared with Sutent in the first-line treatment of patients with advanced renal cell carcinoma.

Cabometyx Combo Maintains Progression-Free Survival Benefit in Advanced RCC

February 15th 2025, 8:54pm

By Ariana Pelosci

Article

Final results were consistent with previously conducted research in patients with advanced renal cell carcinoma treated with Cabometyx, Opdivo and Yervoy.

Antitumor Activity Elicited in ccRCC Following Lenvima/Welireg Treatment

February 15th 2025, 8:43pm

By Roman Fabbricatore

Article

Among patients with clear cell renal cell carcinoma, improved responses were observed with Lenvima plus Welireg versus Keytruda plus Lenvima.

FDA-Approved Fotivda Dose More Effective Than Reduced Dose in RCC

February 15th 2025, 8:04pm

By Kyle Doherty

Article

Researchers showed that 1.34 mg of Fotivda provided decreased tumor size and may be more tolerable than an 0.89-mg dose among patients with renal cell carcinoma.

Bavencio Has Efficacy in The Real-World Treatment of Urothelial Cancer

February 15th 2025, 6:00pm

By Dr. Robert Jones

Article

Following treatment with Bavencio, patients with urothelial cancer lived for 17 months and their cancer remained stable for nine months.

Padcev Significantly Improves OS in Real-World Urothelial Carcinoma

February 15th 2025, 5:25pm

By Morgan Bayer

Article

Among patients in the real world with unresectable or metastatic urothelial carcinoma, Padcev significantly improved overall survival outcomes.

Understanding How One Must Interpret PSA Levels in Prostate Cancer

February 14th 2025, 10:00pm

By Dr. Barry W. Goy

Video

Dr. Barry W. Goy explains how to interpret PSA levels after prostate cancer treatment and how to manage recurrence based on disease progression.

Padcev Plus Keytruda Shows Promise for Upper Tract Urothelial Carcinoma Lesions

February 14th 2025, 9:32pm

By Jason M Broderick

Article

Results from a small retrospective analysis of patients with upper tract urothelial carcinoma lesions were shared at the 2025 ASCO Genitourinary Cancers Symposium.